...
首页> 外文期刊>Clinical Pharmacology and Therapeutics >Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
【24h】

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes

机译:拉帕替尼诱发的以II类HLA和吉尔伯特综合征基因型为特征的肝损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Lapatinib is a clinically important component of the treatment for HER2-positive metastatic breast cancer and has an acceptable safety profile. Lapatinib-associated Hy's Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB107:01 and Gilbert's syndrome UGT1A1*28/*28 genotypes. The HLA-positive cases had higher alanine aminotransferase (ALT) elevation, whereas the HLA-negative cases had a higher incidence of Gilbert's syndrome. The findings of our study, which extend this HLA association to lapatinib-associated serious liver injury, emphasize the importance of Gilbert's syndrome in the interpretation of Hy's Law and may lead to methods for enhancing patient safety.
机译:拉帕替尼是治疗HER2阳性转移性乳腺癌的临床重要组成部分,并具有可接受的安全性。使用人类白细胞抗原(HLA)DQA1 * 02:01 / DRB107:01和吉尔伯特综合征UGT1A1 * 28 / * 28基因型来表征与拉帕替尼相关的Hy's Law病例。 HLA阳性病例的丙氨酸转氨酶(ALT)升高更高,而HLA阴性病例的吉尔伯特综合征发生率更高。我们的研究结果将这种HLA关联扩大到了与拉帕替尼相关的严重肝损伤,强调了吉尔伯特综合征在解释Hy's法则中的重要性,并可能导致提高患者安全性的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号